Covance Wins “Best CRO” Award for Supporting Global Vaccine Development
Covance recognized for providing superior vaccine services to biopharmaceutical industry.
Princeton, NJ-May 5, 2008-Covance (
“This recognition reaffirms our commitment to providing vaccine services that encompass all phases of development,” said Wendel Barr, chief operating officer for Covance. “We understand that each vaccine is unique, and therefore we offer services and experience-including scientific, technical, and regulatory expertise-across different types of vaccines to help guide our customers through the complexities of vaccine development.”
A panel of international judges selected Covance based on the company’s state-of-the-art facilities, vaccine services, and superior customer relations that together help biopharmaceutical companies speed vaccine development. The ViE Awards were created to honor and generate public recognition of the efforts, accomplishments, and positive contributions of organizations and individuals in the global vaccine industry.
The global vaccine market generated sales of $13.5 billion in 2006 and is expected to reach $24.8 billion by 2013, according to a 2007 report published by Wood Mackenzie, a research and consulting firm.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025